Lacopat

Lacosamide, the active ingredient in Lacopat, is a sodium channel blocker presented as an oral formulation for oral use. It is employed as adjunctive therapy for partial‑onset seizures in epilepsy and for primary generalized tonic‑clonic seizures in patients requiring additional seizure control.

GNH USA supplies Lacopat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive documentation, batch traceability, and responsive technical support.

Lacosamide is used as an adjunctive anticonvulsant in the management of seizure disorders. - Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy. - Primary generalized tonic‑clonic seizures: provides additional seizure control as adjunctive treatment. - Epilepsy (overall): contributes to overall seizure management in patients with refractory epilepsy.

Lacosamide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: feeling of tiredness or reduced energy. - Vision changes: blurred or double vision. - Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects: - Cardiac arrhythmia: abnormal heart rhythm, including PR interval prolongation. - Atrioventricular block: impaired conduction between atria and ventricles. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive ideation or suicidal behavior.

When prescribing lacosamide, clinicians should consider several safety and handling precautions. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic dysfunction: monitor liver enzymes and consider dose modification. - Cardiac conduction: evaluate ECG for PR interval prolongation before initiating therapy. - Concomitant antiepileptics: assess for additive CNS depression. - Pregnancy and lactation: use only if potential benefit outweighs risk, as data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lacosamide plasma levels, decreasing effectiveness. - Concomitant use with other sodium channel blockers: increased risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors: may raise lacosamide concentrations, requiring monitoring. - Anticoagulants (e.g., warfarin): potential for altered bleeding risk. - Other antiepileptic drugs: may require dose adjustments based on therapeutic response.